Skip to content
Novo Nordisk
-
Indian pharma giants launch generic Semaglutide as Novo Nordisk patent expires
The companies are competing for a share of India’s Semaglutide market, which analysts estimate will reach USD1 billion over the next two years.
-
Novo Nordisk invests USD470M to expand GLP-1 tablet production in Ireland
The tabletting facility in Athlone represents a cornerstone of Novo Nordisk’s long-term strategy to strengthen its presence in Ireland and enhance its global manufacturing footprint.
-
Novo Nordisk collaborates with Vivtex to develop oral biologic medicines for obesity
The agreement grants Novo Nordisk licensing rights to select oral drug-delivery technologies from Vivtex.